Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
![]() |
Exploratory investigation of virtual lesions in gastrointestinal endoscopy using a novel phase-shift method for three-dimensional shape measurementDEN open, 2025-04, Vol.5 (1), p.e381-e381 [Peer Reviewed Journal]2024 The Authors. DEN Open published by John Wiley & Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society. ;2024 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society. ;EISSN: 2692-4609 ;DOI: 10.1002/deo2.381 ;PMID: 38725875Full text available |
2 |
Material Type: Article
|
![]() |
Treatment of spinal cord injury with biomaterials and stem cell therapy in non-human primates and humansNeural regeneration research, 2025-02, Vol.20 (2), p.343-353 [Peer Reviewed Journal]Copyright © 2025 Copyright: © 2025 Neural Regeneration Research. ;ISSN: 1673-5374 ;DOI: 10.4103/NRR.NRR-D-23-01752 ;PMID: 38819038Full text available |
3 |
Material Type: Article
|
![]() |
Additive neurorestorative effects of exercise and docosahexaenoic acid intake in a mouse model of Parkinson's diseaseNeural regeneration research, 2025-02, Vol.20 (2), p.574 [Peer Reviewed Journal]Copyright © 2025 Copyright: © 2025 Neural Regeneration Research. ;ISSN: 1673-5374 ;PMID: 38819068Full text available |
4 |
Material Type: Article
|
![]() |
Aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders: progress of experimental models based on disease pathogenesisNeural regeneration research, 2025-02, Vol.20 (2), p.354-365 [Peer Reviewed Journal]Copyright © 2025 Copyright: © 2025 Neural Regeneration Research. ;ISSN: 1673-5374 ;EISSN: 1876-7958 ;DOI: 10.4103/NRR.NRR-D-23-01325 ;PMID: 38819039Full text available |
5 |
Material Type: Article
|
![]() |
An update of predictive biomarkers related to WEE1 inhibition in cancer therapyJournal of cancer research and clinical oncology, 2025-01, Vol.150 (1) [Peer Reviewed Journal]The Author(s) 2024 ;ISSN: 0171-5216 ;EISSN: 1432-1335 ;DOI: 10.1007/s00432-023-05527-yDigital Resources/Online E-Resources |
6 |
Material Type: Article
|
![]() |
Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2− breast cancer: an umbrella reviewJournal of cancer research and clinical oncology, 2025-01, Vol.150 (1) [Peer Reviewed Journal]The Author(s) 2024 ;ISSN: 0171-5216 ;EISSN: 1432-1335 ;DOI: 10.1007/s00432-023-05516-1Digital Resources/Online E-Resources |
7 |
Material Type: Article
|
![]() |
Predictive biomarkers for immunotherapy response in extensive-stage SCLCJournal of cancer research and clinical oncology, 2025-01, Vol.150 (1) [Peer Reviewed Journal]The Author(s) 2024 ;ISSN: 0171-5216 ;EISSN: 1432-1335 ;DOI: 10.1007/s00432-023-05544-xDigital Resources/Online E-Resources |
8 |
Material Type: Article
|
![]() |
Immunogenic profiling of metastatic uveal melanoma discerns a potential signature related to prognosisJournal of cancer research and clinical oncology, 2025-01, Vol.150 (1) [Peer Reviewed Journal]The Author(s) 2024 ;ISSN: 0171-5216 ;EISSN: 1432-1335 ;DOI: 10.1007/s00432-023-05542-zDigital Resources/Online E-Resources |
9 |
Material Type: Article
|
![]() |
Prognostic value of preoperative circulating tumor DNA in non-small cell lung cancer: a systematic review and meta-analysisJournal of cancer research and clinical oncology, 2025-01, Vol.150 (1) [Peer Reviewed Journal]The Author(s) 2024 ;ISSN: 0171-5216 ;EISSN: 1432-1335 ;DOI: 10.1007/s00432-023-05550-zDigital Resources/Online E-Resources |
10 |
Material Type: Article
|
![]() |
Natural products targeting the MAPK-signaling pathway in cancer: overviewJournal of cancer research and clinical oncology, 2025-01, Vol.150 (1) [Peer Reviewed Journal]The Author(s) 2024 ;ISSN: 0171-5216 ;EISSN: 1432-1335 ;DOI: 10.1007/s00432-023-05572-7Digital Resources/Online E-Resources |
11 |
Material Type: Article
|
![]() |
Hypofractionated versus standard chemoradiotherapy in the definitive treatment of uterine cervix cancer: interim results of a randomized controlled clinical trialJournal of cancer research and clinical oncology, 2025-01, Vol.150 (1) [Peer Reviewed Journal]The Author(s) 2024 ;ISSN: 0171-5216 ;EISSN: 1432-1335 ;DOI: 10.1007/s00432-023-05563-8Digital Resources/Online E-Resources |
12 |
Material Type: Article
|
![]() |
Exploiting fly models to investigate rare human neurological disordersNeural regeneration research, 2025-01, Vol.20 (1), p.21-28 [Peer Reviewed Journal]Copyright © 2025 Copyright: © 2025 Neural Regeneration Research. ;ISSN: 1673-5374 ;DOI: 10.4103/NRR.NRR-D-23-01847 ;PMID: 38767473Full text available |
13 |
Material Type: Article
|
![]() |
Recent progress in the applications of presynaptic dopaminergic positron emission tomography imaging in parkinsonismNeural regeneration research, 2025-01, Vol.20 (1), p.93-106 [Peer Reviewed Journal]Copyright © 2025 Copyright: © 2025 Neural Regeneration Research. ;ISSN: 1673-5374 ;EISSN: 1876-7958 ;DOI: 10.4103/1673-5374.391180 ;PMID: 38767479Full text available |
14 |
Material Type: Article
|
![]() |
Efficacy and safety of first-line therapy in patients with HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trialsJournal of cancer research and clinical oncology, 2025-01, Vol.150 (1) [Peer Reviewed Journal]The Author(s) 2024 ;ISSN: 0171-5216 ;EISSN: 1432-1335 ;DOI: 10.1007/s00432-023-05530-3Digital Resources/Online E-Resources |
15 |
Material Type: Article
|
![]() |
Antibody persistence to diphtheria toxoid, tetanus toxoid, Bordetella pertussis antigens, and Haemophilus influenzae type b following primary and first booster with pentavalent versus hexavalent vaccinesHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2352909-2352909 [Peer Reviewed Journal]ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2352909 ;PMID: 38752802Full text available |
16 |
Material Type: Article
|
![]() |
Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocolHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2348135-2348135 [Peer Reviewed Journal]2024 The Author(s). Published with license by Taylor & Francis Group, LLC. 2024 The Author(s) ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2348135 ;PMID: 38738683Full text available |
17 |
Material Type: Article
|
![]() |
Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adultsHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2304974-2304974 [Peer Reviewed Journal]2024 The Author(s). Published with license by Taylor & Francis Group, LLC. 2024 The Author(s) ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2304974 ;PMID: 38512394Full text available |
18 |
Material Type: Article
|
![]() |
Toll-like receptor agonists as cancer vaccine adjuvantsHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2297453-2297453 [Peer Reviewed Journal]2023 The Author(s). Published with license by Taylor & Francis Group, LLC. 2023 The Author(s) ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2023.2297453 ;PMID: 38155525Full text available |
19 |
Material Type: Article
|
![]() |
LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcomaOncoimmunology, 2024-12, Vol.13 (1), p.2290900-2290900 [Peer Reviewed Journal]2023 The Author(s). Published with license by Taylor & Francis Group, LLC. ;2023 The Author(s). Published with license by Taylor & Francis Group, LLC. 2023 The Author(s) ;ISSN: 2162-402X ;ISSN: 2162-4011 ;EISSN: 2162-402X ;DOI: 10.1080/2162402X.2023.2290900 ;PMID: 38125722Full text available |
20 |
Material Type: Article
|
![]() |
Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): Finding from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteersHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2301631-2301631 [Peer Reviewed Journal]2024 The Author(s). Published with license by Taylor & Francis Group, LLC. 2024 The Author(s) ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2023.2301631 ;PMID: 38189360Full text available |